867,284 Shares in Jade Biosciences, Inc. $JBIO Bought by Aberdeen Group plc

Aberdeen Group plc acquired a new position in shares of Jade Biosciences, Inc. (NASDAQ:JBIO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 867,284 shares of the company’s stock, valued at approximately $13,382,000. Aberdeen Group plc owned 1.76% of Jade Biosciences at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Frazier Life Sciences Management L.P. bought a new stake in shares of Jade Biosciences during the 2nd quarter worth $17,703,000. XTX Topco Ltd bought a new stake in shares of Jade Biosciences during the 2nd quarter worth $257,000. Soleus Capital Management L.P. bought a new position in Jade Biosciences in the 2nd quarter worth approximately $7,959,000. Sofinnova Investments Inc. bought a new position in Jade Biosciences in the 2nd quarter worth approximately $1,073,000. Finally, Rhumbline Advisers bought a new position in Jade Biosciences in the 2nd quarter worth approximately $445,000.

Jade Biosciences Price Performance

Shares of Jade Biosciences stock opened at $16.36 on Wednesday. The firm has a market capitalization of $806.88 million, a PE ratio of -3.55 and a beta of 1.03. The company’s fifty day moving average price is $14.60 and its two-hundred day moving average price is $12.99. Jade Biosciences, Inc. has a 52-week low of $6.57 and a 52-week high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last posted its earnings results on Friday, March 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.34.

Analyst Ratings Changes

Several research analysts have commented on JBIO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jade Biosciences in a research report on Monday, December 29th. William Blair raised Jade Biosciences to a “strong-buy” rating in a research report on Monday, March 9th. BTIG Research lifted their price target on Jade Biosciences from $28.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Wedbush reaffirmed an “outperform” rating and issued a $24.00 price target on shares of Jade Biosciences in a research report on Monday, March 9th. Finally, Guggenheim lifted their price target on Jade Biosciences from $17.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Jade Biosciences Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.